RSS
TwitterFacebook

Generic Diovan Recall Issued Over Cancer Risks Worldwide, But Not In U.S.

  • Written by: Irvin Jackson
  • 5 Comments

Nearly two dozen countries worldwide have announced a recall for generic Diovan, indicating that impurities were detected in the hypertension and heart drug that may cause cancer. 

The valsartan recall was announced on July 5, after batches of the active ingredient, supplied by Zhejiang Huahai Pharmaceuticals in China, tested positive for N-nitrosodimethylamine (NDMA). The recall affects about 2,300 batches of valsartan and valsartan HCT shipped throughout Europe and Canada, but it does not appear the recalled medications were shipped in the United States.

The European Medicines Agency (EMA) issued a press release announcing a safety review of the drugs the same day the worldwide generic Diovan recall was announced.

“NDMA is classified as a probably human carcinogen (a substance that could cause cancer) based on results from laboratory tests. The presence of NDMA was unexpected and is thought to be related to changes in the wat the active substance was manufactured,” the EMA press release states. “While the review is underway, national authorities across the EU are recalling the medicines containing valsartan supplied by Zhejiang Huahai.”

The review will look at the levels of NDMA found in valsartan and the potential health effects, as well as what can be done for patients who have taken them, and how future contamination can be prevented.

Officials in the U.S. Food and Drug Administration (FDA) have declined to say whether any of the batches were shipped to the United States, and are not recalling any valsartan at this time.

The FDA reviewed Diovan and similar medications in 2010, after some data suggested they may increase the risk of cancer. However, in 2011, the FDA reviewers indicated they could find no link between the drugs, known as angiotensin receptor blockers (ARBs) and cancer.

It is unclear whether the 2010 review and cancer concerns are connected in any way to last week’s recall. Valsartan was originally developed and sold by Novartis, and is now off-patent and sold as a generic.

Tags: , , , , ,

5 comments

  1. Laura Reply

    Absolutely, awful…

  2. Kimberly Reply

    This is horrible! As a healthcare provider, I appalled that this happens!

  3. cindy Reply

    what a scare! I have been on Valsartan for several years now and although it has not been recalled in the US it’s still scary. I had endometrosis cancer last year with a full hysterectomy

  4. Richard Reply

    I have been taking the Valsartan/HCTZ medication distributed by Solco– which was manufactured by a chines company- and I am concerned that I could be faced with potential , life threatening cancer -due to exposure to the cancer causing NDMA- which has been found in this recalled medication.
    I see a class action lawsuit filed in Canada- can you tell me of any firm(s) that may be filing class action suit here in the US-which I could join in?
    I would like for any future medical costs to be covered by these firms- and also would like to see the FDA in this country- ban any medications from China- or other countries which we have limited control, or supervision over.
    Any help would be appreciated……this has to investigated- and stopped…..and all patients should be compensated for possible future medical costs.
    I welcome your response, and any help in forwarding these comments to any law firms that may wish to take this on.
    Thank you.

  5. Dina Reply

    My mother was on Diovan for years. My father frequently bought medications from Canadian pharmaceutical companies because they couldn’t afford their medications otherwise. She died of stage 4 lung cancer last year. Makes me wonder if this had something to do with it.

  • Share Your Comments

  • Have Your Comments Reviewed by a Lawyer

    Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.
  • NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.